Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Investors Business Daily
Investors Business Daily
Technology
INVESTOR'S BUSINESS DAILY and JULIE MAK

Apellis Pharmaceuticals Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating

When looking for the best stocks to buy and watch, focus on those with rising relative price strength.

One stock that fits that bill is ApellisPharmaceuticals stock, which had its Relative Strength (RS) Rating upgraded from 79 to 85 Friday.

When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

This unique rating measures market leadership by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the trailing 52 weeks matches up against the rest of the market.

Decades of market research shows that the top-performing stocks typically have an RS Rating north of 80 as they launch their biggest price moves.

Looking For The Best Stocks To Buy And Watch? Start Here

Is Apellis Pharmaceuticals Stock A Buy?

Apellis Pharmaceuticals stock is building a cup without handle with a 60.30 buy point. See if the stock can break out in volume at least 40% above average. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.

 

While sales growth fell last quarter from 769% to -76%, EPS grew 32%, up from 0% in the prior report.

Apellis Pharmaceuticals stock holds the No. 93 rank among its peers in the Medical-Biomed/Biotech industry group. Corcept Therapeutics and Dynavax Technologies are also among the group's highest-rated stocks. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News".

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.